| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00595-012-0392-5 |
| P698 | PubMed publication ID | 23129027 |
| P2093 | author name string | Hisahiro Matsubara | |
| Isamu Hoshino | |||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| Principles of microRNA-target recognition | Q21146368 | ||
| MicroRNAs and their target gene networks in breast cancer | Q21195211 | ||
| Translating the Histone Code | Q22065840 | ||
| Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia | Q24539231 | ||
| Accumulation of miR-155 and BIC RNA in human B cell lymphomas | Q24556523 | ||
| MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias | Q24564008 | ||
| Characterization of extracellular circulating microRNA | Q24603537 | ||
| miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis | Q24613599 | ||
| Epigenetics and environmental chemicals | Q24629035 | ||
| miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer | Q24630894 | ||
| MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4 | Q24633718 | ||
| MicroRNAs: new players in cardiac injury and protection | Q24635236 | ||
| MicroRNA let-7: an emerging next-generation cancer therapeutic | Q24644251 | ||
| Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma | Q24646667 | ||
| A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis | Q24649156 | ||
| Circulating microRNAs as stable blood-based markers for cancer detection | Q24652098 | ||
| MicroRNA-373 induces expression of genes with complementary promoter sequences | Q24652547 | ||
| miR-34a repression of SIRT1 regulates apoptosis | Q24652720 | ||
| Effects of let-7 microRNA on Cell Growth and Differentiation of Papillary Thyroid Cancer | Q24652758 | ||
| MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma | Q24653676 | ||
| Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype | Q24656088 | ||
| Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-kappaB pathway | Q24657973 | ||
| Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice | Q24675006 | ||
| Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) | Q24681480 | ||
| Hidden reach of the micromanagers. | Q27692612 | ||
| Unique microRNA molecular profiles in lung cancer diagnosis and prognosis | Q27860631 | ||
| MicroRNA gene expression deregulation in human breast cancer | Q27860690 | ||
| c-Myc-regulated microRNAs modulate E2F1 expression | Q27861046 | ||
| MicroRNA expression profiles classify human cancers | Q28032481 | ||
| Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases | Q28131780 | ||
| MicroRNA-directed cleavage of HOXB8 mRNA | Q28131834 | ||
| let-7 microRNA functions as a potential growth suppressor in human colon cancer cells | Q28237683 | ||
| The miR-34 family in cancer and apoptosis | Q28245865 | ||
| Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells | Q28249223 | ||
| The role of let-7 in cell differentiation and cancer | Q28259549 | ||
| let-7 regulates self renewal and tumorigenicity of breast cancer cells | Q28261263 | ||
| Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival | Q28264400 | ||
| The let-7 microRNA reduces tumor growth in mouse models of lung cancer | Q28272817 | ||
| MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation | Q28281118 | ||
| Let-7 microRNA inhibits the proliferation of human glioblastoma cells | Q28287254 | ||
| A microRNA component of the p53 tumour suppressor network | Q28305330 | ||
| Regulatory circuit of human microRNA biogenesis | Q35753722 | ||
| Cancer epigenetics: above and beyond | Q35844494 | ||
| Expression profiling of microRNA using oligo DNA arrays | Q35876067 | ||
| Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure | Q35964249 | ||
| Array comparative genomic hybridization and its applications in cancer | Q36141621 | ||
| MicroRNAs in body fluids--the mix of hormones and biomarkers | Q36176435 | ||
| MicroRNA expression profiles of esophageal cancer | Q36490960 | ||
| Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer | Q36657641 | ||
| Loss of imprinting and cancer | Q36687286 | ||
| Mechanisms of disease: methyl-binding domain proteins as potential therapeutic targets in cancer | Q36803783 | ||
| CpG island hypermethylation of tumor suppressor microRNAs in human cancer | Q36854202 | ||
| Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia | Q36910441 | ||
| Epigenetics: relations to disease and laboratory findings | Q36990253 | ||
| Chromatin-remodelling mechanisms in cancer. | Q37134923 | ||
| HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells | Q37150773 | ||
| 14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. | Q37165239 | ||
| C19MC microRNAs are processed from introns of large Pol-II, non-protein-coding transcripts | Q37215383 | ||
| microRNAs and cancer: an overview | Q37249283 | ||
| Beyond HPV: oncomirs as new players in cervical cancer | Q37334551 | ||
| SNPs in human miRNA genes affect biogenesis and function | Q37344542 | ||
| Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo | Q37346696 | ||
| Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. | Q37400592 | ||
| MicroRNA regulatory network in human colorectal cancer | Q37551006 | ||
| Genome-wide hypomethylation in cancer may be a passive consequence of transformation | Q37732576 | ||
| PI(3)king apart PTEN's role in cancer. | Q37771785 | ||
| Dysregulation of microRNAs in cancer: playing with fire | Q37779828 | ||
| Recent advances in histone deacetylase targeted cancer therapy | Q37782569 | ||
| MicroRNA dysregulation in gastric cancer: a new player enters the game | Q37783909 | ||
| MicroRNAs, epigenetics and disease | Q37785997 | ||
| Histone modifications and cancer | Q37797690 | ||
| Histone lysine methylation and demethylation pathways in cancer | Q37800638 | ||
| Methods for the discovery of low-abundance biomarkers for urinary bladder cancer in biological fluids. | Q37810251 | ||
| Oncogenic microRNAs (OncomiRs) as a new class of cancer biomarkers | Q37812094 | ||
| Epigenetic aberrations during oncogenesis. | Q37830385 | ||
| Clinical significance of astrocyte elevated gene-1 expression in human epithelial ovarian carcinoma | Q44696506 | ||
| Profiling of Epstein-Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs. | Q44833814 | ||
| 14-3-3ζ positive expression is associated with a poor prognosis in patients with glioblastoma | Q46717742 | ||
| Lats2 is an essential mitotic regulator required for the coordination of cell division. | Q51987013 | ||
| Expression of astrocyte elevated gene-1: a novel marker of the pathogenesis, progression, and poor prognosis for endometrial cancer. | Q53155160 | ||
| miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. | Q53306726 | ||
| MicroRNA-373 (miR-373) post-transcriptionally regulates large tumor suppressor, homolog 2 (LATS2) and stimulates proliferation in human esophageal cancer. | Q53309576 | ||
| miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. | Q54357850 | ||
| Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. | Q54382778 | ||
| miR-21 microRNA expression in human gastric carcinomas and its clinical association | Q81346254 | ||
| Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes | Q82468133 | ||
| Significance of AEG-1 expression in correlation with VEGF, microvessel density and clinicopathological characteristics in triple-negative breast cancer | Q83275662 | ||
| Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas | Q83324615 | ||
| DNA hypermethylation of microRNA-34b/c has prognostic value for stage Ⅰ non-small cell lung cancer | Q83557235 | ||
| MicroRNA regulation of DNA repair gene expression in hypoxic stress | Q28306694 | ||
| CpG islands and the regulation of transcription | Q28315762 | ||
| Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer | Q28478758 | ||
| MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer | Q29547523 | ||
| Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis | Q29547575 | ||
| Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma | Q29614238 | ||
| A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors | Q29614399 | ||
| Non-coding RNAs in human disease | Q29618039 | ||
| Transcriptional activation of miR-34a contributes to p53-mediated apoptosis | Q29619556 | ||
| Towards the human cancer epigenome: a first draft of histone modifications | Q33341651 | ||
| microRNAs join the p53 network--another piece in the tumour-suppression puzzle | Q33344707 | ||
| Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth | Q33348593 | ||
| FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension | Q33365592 | ||
| Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres | Q33370714 | ||
| Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. | Q33385245 | ||
| Features of mammalian microRNA promoters emerge from polymerase II chromatin immunoprecipitation data | Q33434396 | ||
| Detection of cancer with serum miRNAs on an oligonucleotide microarray | Q33481633 | ||
| MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. | Q33564111 | ||
| Frequent downregulation of miR-34 family in human ovarian cancers | Q33658229 | ||
| Structure and activity of putative intronic miRNA promoters | Q33658452 | ||
| MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival | Q33748264 | ||
| Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers | Q33886925 | ||
| Binding of NF-kappaB p65 subunit to the promoter elements is involved in LPS-induced transactivation of miRNA genes in human biliary epithelial cells | Q33889371 | ||
| Upregulation of MiR-155 in nasopharyngeal carcinoma is partly driven by LMP1 and LMP2A and downregulates a negative prognostic marker JMJD1A. | Q33889404 | ||
| MicroRNA delivery by cationic lipoplexes for lung cancer therapy | Q34060310 | ||
| Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas | Q34097908 | ||
| MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta | Q34103001 | ||
| MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene | Q34107532 | ||
| Tumor-suppressive mir-663 gene induces mitotic catastrophe growth arrest in human gastric cancer cells | Q34118383 | ||
| Active DNA demethylation: many roads lead to Rome. | Q34129576 | ||
| OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. | Q34130311 | ||
| Exosomes/microvesicles as a mechanism of cell-to-cell communication | Q34130853 | ||
| MicroRNA sponges: progress and possibilities | Q34139023 | ||
| Targeting microRNAs in cancer: rationale, strategies and challenges | Q34141089 | ||
| Connecting chromosomes, crisis, and cancer | Q34141381 | ||
| Circulating microRNAs: possible prediction biomarkers for personalized therapy of non-small-cell lung carcinoma | Q37832870 | ||
| MicroRNAs and epigenetics | Q37852129 | ||
| MicroRNAs as therapeutic targets in cancer | Q37855085 | ||
| MicroRNAs as biomarkers of disease onset. | Q37872226 | ||
| DNA methylation in cancer development, diagnosis and therapy--multiple opportunities for genotoxic agents to act as methylome disruptors or remediators. | Q37873228 | ||
| Romidepsin: a novel histone deacetylase inhibitor for cancer | Q37893664 | ||
| MicroRNA regulation by RNA-binding proteins and its implications for cancer | Q37913018 | ||
| Big roles of microRNAs in tumorigenesis and tumor development | Q37922684 | ||
| Regulation of microRNA expression and function by nuclear receptor signaling | Q37936584 | ||
| MicroRNAs in rhabdomyosarcoma: pathogenetic implications and translational potentiality | Q37937737 | ||
| Evaluation of online miRNA resources for biomedical applications. | Q37955258 | ||
| DNA methylation of tumor suppressor miRNA genes: a lesson from the miR-34 family | Q37962577 | ||
| Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers | Q37989885 | ||
| MicroRNA expression profiles in head and neck cancer cell lines | Q38302158 | ||
| MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). | Q38303663 | ||
| Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells. | Q38318992 | ||
| Overexpression of AEG-1 in renal cell carcinoma and its correlation with tumor nuclear grade and progression | Q38414708 | ||
| MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo | Q39447513 | ||
| Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer | Q39448960 | ||
| Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region Y box 6 in hepatocellular carcinoma. | Q39459780 | ||
| MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor | Q39495719 | ||
| Tumor suppressive microRNA-375 regulates oncogene AEG-1/MTDH in head and neck squamous cell carcinoma (HNSCC). | Q39507167 | ||
| Epigenetic regulation of microRNA-375 and its role in melanoma development in humans. | Q39514244 | ||
| Epigenetic silencing of microRNA-375 regulates PDK1 expression in esophageal cancer | Q39550203 | ||
| Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer | Q39592978 | ||
| Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas | Q39608984 | ||
| Signatures of microRNAs and selected microRNA target genes in human melanoma. | Q39707682 | ||
| miR-21: an oncomir on strike in prostate cancer. | Q39749407 | ||
| Nuclear factor-{kappa}B contributes to anaplastic thyroid carcinomas through up-regulation of miR-146a | Q39753969 | ||
| MicroRNA let-7a represses chemoresistance and tumourigenicity in head and neck cancer via stem-like properties ablation. | Q39786661 | ||
| MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor | Q39840690 | ||
| Specificity and functionality of microRNA inhibitors | Q39886691 | ||
| MicroRNA-like off-target transcript regulation by siRNAs is species specific. | Q39895165 | ||
| MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas | Q40073679 | ||
| p53-mediated activation of miRNA34 candidate tumor-suppressor genes. | Q40102003 | ||
| Selective silencing of the hypoxia-inducible factor 1 target gene BNIP3 by histone deacetylation and methylation in colorectal cancer | Q40262845 | ||
| Sequence variations of microRNAs in human cancer: alterations in predicted secondary structure do not affect processing. | Q40267038 | ||
| Spi-1/PU.1: an oncogene of the Ets family | Q40567919 | ||
| MicroRNAs 373 and 520c are downregulated in prostate cancer, suppress CD44 translation and enhance invasion of prostate cancer cells in vitro. | Q42147457 | ||
| Transcriptional repression of miR-34 family contributes to p63-mediated cell cycle progression in epidermal cells | Q42466132 | ||
| Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma | Q42942114 | ||
| Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells | Q43191223 | ||
| MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients | Q44273844 | ||
| NF-kappaB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway | Q34143653 | ||
| Circulating microRNAs (miRNA) in serum of patients with prostate cancer | Q34182161 | ||
| Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. | Q34209735 | ||
| 14-3-3ζ as a prognostic marker and therapeutic target for cancer | Q34473399 | ||
| Epigenetic gene silencing in cancer: the DNA hypermethylome | Q34646556 | ||
| Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer | Q34711457 | ||
| Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. | Q34712578 | ||
| Epigenetics: a historical overview | Q34713017 | ||
| Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer | Q34720476 | ||
| MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility | Q34749465 | ||
| Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. | Q34811436 | ||
| Latent membrane protein-1 of Epstein-Barr virus induces the expression of B-cell integration cluster, a precursor form of microRNA-155, in B lymphoma cell lines | Q34858379 | ||
| MiR-34, SIRT1 and p53: the feedback loop | Q34946471 | ||
| Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival | Q34988674 | ||
| MicroRNA in central nervous system trauma and degenerative disorders | Q35033677 | ||
| Shielding the messenger (RNA): microRNA-based anticancer therapies | Q35070602 | ||
| MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. | Q35070803 | ||
| Human cytomegalovirus US7 is regulated synergistically by two virally encoded microRNAs and by two distinct mechanisms. | Q35531336 | ||
| Linking the epigenetic 'language' of covalent histone modifications to cancer | Q35670206 | ||
| Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications | Q35734509 | ||
| P433 | issue | 5 | |
| P921 | main subject | microRNA | Q310899 |
| cancer diagnosis | Q110324059 | ||
| P304 | page(s) | 467-478 | |
| P577 | publication date | 2012-11-06 | |
| P1433 | published in | Surgery Today | Q15765823 |
| P1476 | title | MicroRNAs in cancer diagnosis and therapy: from bench to bedside | |
| P478 | volume | 43 |
| Q53670271 | Associations between polymorphisms of HOTAIR and risk of gastric cardia adenocarcinoma in a population of north China. |
| Q52877633 | Can hyperthermic intraperitoneal chemotherapy efficiency be improved by blocking the DNA repair factor COP9 signalosome? |
| Q86823681 | Circulating cell-free microRNAs as biomarkers for colorectal cancer |
| Q49148462 | Clinical Significance of Histone Demethylase NO66 in Invasive Colorectal Cancer. |
| Q26798147 | Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer |
| Q38624837 | Emerging techniques in the isolation and characterization of extracellular vesicles and their roles in cancer diagnostics and prognostics |
| Q39254692 | Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer. |
| Q33801377 | Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects |
| Q35863159 | Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer |
| Q38950194 | Expression of microRNA-96 and its potential functions by targeting FOXO3 in non-small cell lung cancer |
| Q33574284 | Inhibition of cell proliferation and migration by miR-509-3p that targets CDK2, Rac1, and PIK3C2A. |
| Q35814865 | MicroRNA library screening identifies growth-suppressive microRNAs that regulate genes involved in cell cycle progression and apoptosis. |
| Q90441365 | MicroRNA-34a suppresses breast cancer cell proliferation and invasion by targeting Notch1 |
| Q33643578 | Microrna-124 targets flotillin-1 to regulate proliferation and migration in breast cancer |
| Q28386642 | Nanomaterials and autophagy: new insights in cancer treatment |
| Q36376636 | Notch ligand Delta-like 1 as a novel molecular target in childhood neuroblastoma |
| Q38806970 | The Clinical Impact of Transcatheter Arterial Chemoembolization (TACE)-Induced c-Met Upregulation on TACE Refractoriness in Hepatocellular Carcinoma |
| Q34484455 | miR-200c inhibits invasion, migration and proliferation of bladder cancer cells through down-regulation of BMI-1 and E2F3 |
| Q40773825 | miR-615-3p expression level in bone marrow is associated with tumor recurrence in hepatocellular carcinoma |
Search more.